title: 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.
abstract: OBJECTIVE
  Breast cancer is the second cause of death in women in Europe and North America. The mortality of this disease can be reduced with effective therapy and regular follow up to detect early recurrence. Tumor markers are sensitive in detecting recurrent or residual disease but imaging is required to customize the therapeutic option. Rising tumor markers and negative conventional imaging (US, X-mammography, CT and MR) poses a management problem. Our aim is to assess the role of 18F-FDG-PET/CT in the management of post-therapy patients with rising markers but negative conventional imaging.
  
  
  METHODS
  In the period from January 2008 to September 2009, 89 female patients with breast cancer who developed post-therapy rising markers (serum Ca 15-3 levels=64.8±16.3 U/mL) but negative clinical examination and conventional imaging were investigated with 18F-FDG-PET/CT.
  
  
  RESULTS
  Tumor deposits were detected in 40/89 patients in chest wall, internal mammary nodes, lungs, liver and skeleton. The mean SUVmax value calculated in these lesions was 6.6±1.7 (range 3.1-12.8). In 23/40 patients solitary small lesion were amenable to radical therapy. In 7 out of these 23 patients a complete disease remission lasting more than 1 year was observed.
  
  
  CONCLUSIONS
  18F-FDG-PET/CT may have a potential role in asymptomatic patients with rising markers and negative conventional imaging. Our findings agree with other studies in promoting regular investigations such as tumor markers and 18F-FDG-PET/CT rather than awaiting the developments of physical symptoms as suggested by current guidelines since the timely detection of early recurrence may have a major impact on therapy and survival.
authors.affiliation: Department of Nuclear Medicine, PET/CT Centre, Radiology, Medical Physics, Santa Maria della Misericordia Hospital, Viale Tre Martiri 140, 45100 Rovigo, Italy. gagra57@libero.it
authors.forename: Gaia
authors.initials: G
authors.lastname: Grassetto
authors.forename: Adriano
authors.initials: A
authors.lastname: Fornasiero
authors.forename: Daniele
authors.initials: D
authors.lastname: Otello
authors.forename: Giorgio
authors.initials: G
authors.lastname: Bonciarelli
authors.forename: Elena
authors.initials: E
authors.lastname: Rossi
authors.forename: Ottorino
authors.initials: O
authors.lastname: Nashimben
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Minicozzi
authors.forename: Giorgio
authors.initials: G
authors.lastname: Crepaldi
authors.forename: Felice
authors.initials: F
authors.lastname: Pasini
authors.forename: Enzo
authors.initials: E
authors.lastname: Facci
authors.forename: Giovanni
authors.initials: G
authors.lastname: Mandoliti
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Marzola
authors.forename: Adil
authors.initials: A
authors.lastname: Al-Nahhas
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007558:Italy; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor; D018396:Mucin-1; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18